Progenics Pharmaceuticals buy tamam
Zusammenfassung
Diese Einschätzung wurde am 21.06.19 mit einem Endkurs von 4,65 € beendet. Mit einer Rendite von -20,77 % entwickelte sich die Einschätzung BUY nicht nach Plan. tamam hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
Name | 1W | 1M | 1J | 3J |
---|---|---|---|---|
Progenics Pharmaceuticals | - | - | - | - |
iShares Core DAX® | 2,29 % | 2,98 % | 20,34 % | 20,14 % |
iShares Nasdaq 100 | 1,34 % | -0,20 % | 25,55 % | 37,73 % |
iShares Nikkei 225® | 1,13 % | 2,49 % | 13,16 % | 1,26 % |
iShares S&P 500 | 1,27 % | 1,33 % | 24,54 % | 40,52 % |
Kommentare von tamam zu dieser Einschätzung
In der Diskussion Progenics Pharmaceuticals diskutieren
PGNX with NDA for Azedra Submission 01.09.2017
Progenics Pharmaceuticals has currently one product on the market, Relistor, and has a deep pipeline that has both early and late-stage product candidates, and is broke down into 4 categories: PSMA targeted oncology, oncology, oncology supportive care, and partnered programs.
PGNX has completed a pre- submission meeting for Azedra with the FDA and an NDA submission should follow this month. The drug has been awarded Breakthrough designation and was developed under a SPA. Top line results were released earlier this year and a fuller data set is expected to be presented at the International Symposium of Pheochromocytoma and Paraganglioma on Sept. 1.
Combined with submission of the NDA for Azedra, this should boost the shares significantly. Taking the combined value of relistor, Azedra, other pipeline assets and cash on hand; Progenics could easily double from current trading levels and still sell for less than its intrinsic value.This valuation discount should be narrowed substantially as the prospects for Progenics become clearer for the market in the coming months.